Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Panel OKs 37 More COVID-19 Jab Health Damage Claims for Compensation
September 14, 2021
- Japan Unveils New Pharma Industry Vision, 1st Update in 8 Years
September 14, 2021
- SaMD Would Be Evaluated Like Ordinary Medical Devices: PMDA Official
September 13, 2021
- PMDA Reviewing Safety Risks for Ivermectin, Xeljanz
September 13, 2021
- Causal Link between Deaths and Recalled Batch of Moderna Jab “Indeterminable”
September 13, 2021
- MHLW to Promptly Seek Expert Panel Discussion on Booster Shots: Minister
September 13, 2021
- Japan Should Arrange Boosters Immediately, Mix-and-Match Doses Too: LDP
September 10, 2021
- Regional Governors Club Urges Early Conclusion on HPV Vaccines
September 10, 2021
- COVID-19 Antibody Cocktail Given to 13,000 in Japan by August-End: MHLW
September 10, 2021
- Cabinet Counselor Koichi Ando Tapped as MHLW Economic Affairs Chief
September 8, 2021
- MHLW to Fund Avigan Program, COVID-19 Drugs from AZ, Shionogi
September 8, 2021
- Japan Strikes Deal for 150 Million Novavax Vaccine Doses, Supply Could Start Early Next Year
September 7, 2021
- Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug Clear PAFSC Panel
September 7, 2021
- Pfizer Vaccine Imports Set to Be Completed in October: Minister
September 7, 2021
- MHLW Panel Backs Takeda’s Cell Therapy Darvadstrocel for Complex Anal Fistulas in CD
September 7, 2021
- Drug Makers Should Conduct Joint Inspections at Contract Manufacturers to Prevent GMP Violations: Expert
September 7, 2021
- Entresto Clears MHLW Panel with Strings Attached, It’s Not a 1st Choice Drug
September 6, 2021
- Japan Govt to Accelerate Discussion on Specific Growth Strategy
September 3, 2021
- Nationwide On-Site Inspections Identify GMP Issues at 9 Generic Plants: MHLW
September 3, 2021
- MHLW Panel to Review Entresto’s Hypertension Indication Again on September 3
September 3, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…